Talis Biomedical

Talis Biomedical ROA

Delisted

The Return on Assets (ROA) of Talis Biomedical (TLIS) as of Oct 20, 2026 is -65.50 %. In the previous year, Return on Assets (ROA) was -66.76 % — a change of -1.89% (higher).

ROA

-65.50 %

YoY

-1.89%

Last updated:

In 2023, Talis Biomedical's return on assets (ROA) was -65.50 %, a -1.89% increase from the -66.76 % ROA in the previous year.

The Talis Biomedical ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-187.53 USD
Jan 1, 2019
102.52 USD
Jan 1, 2020
-45.93 USD
Jan 1, 2021
-72.24 USD
Jan 1, 2022
-66.76 USD
Jan 1, 2023
-65.50 USD
The Talis Biomedical ROA history
YEARROAYoY
-65.50 %-1.89%
-66.76 %-7.59%
-72.24 %+57.28%
-45.93 %-144.80%
102.52 %-154.67%
-187.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talis Biomedical Stock analysis

What does Talis Biomedical do? Talis Biomedical Corp develops and commercializes the Talis One system, a cloud-enabled molecular diagnostic platform comprising a compact instrument, single-use test cartridges, and software linked to a central cloud database. The company targets healthcare providers seeking point-of-care molecular testing for infectious diseases, respiratory infections, women's health conditions, and sexually transmitted infections (STIs). Its products include assay kits for respiratory panels combining influenza A, influenza B, and COVID-19 tests, designed for use by untrained personnel. Revenue is generated through sales of the Talis One system and associated assay kits to healthcare facilities requiring rapid, accurate diagnostic solutions. The Talis One system is positioned for central laboratory-level accuracy at the point of care, appealing to clinics and hospitals needing efficient diagnostic tools. The Respiratory Panel, integrating influenza A, influenza B, and COVID-19 assays, addresses high-demand areas in infectious disease testing. The company's focus on women's health and STI-related assays expands its market reach within specialized healthcare segments. Sales of these products are directed toward healthcare providers who prioritize accessible, user-friendly diagnostic technology without requiring extensive training. Talis Biomedical Corp's commercial strategy centers on delivering diagnostic solutions that combine advanced molecular testing with ease of use. The Talis One system and its assay kits are marketed to healthcare facilities aiming to enhance diagnostic capabilities at the point of care. By targeting respiratory infections, women's health, and STIs, the company addresses key areas where rapid, accurate testing is critical. Revenue streams are derived from the sale of both the hardware platform and the consumable test kits, ensuring ongoing customer engagement through recurring purchases. Talis Biomedical is one of the most popular companies on Eulerpool.

ROA Details

Understanding Talis Biomedical's Return on Assets (ROA)

Talis Biomedical's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Talis Biomedical's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Talis Biomedical's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Talis Biomedical’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Talis Biomedical stock

Return on Assets (ROA) of Talis Biomedical is -65.50 % in 2023.

Return on Assets (ROA) of Talis Biomedical changed from -66.76 % to -65.50 %, representing a -1.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Talis Biomedical since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Talis Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Talis Biomedical

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Talis Biomedical